HASI Lifts 2028 EPS Guide to $3.55-$3.65-But Is the Stock Finally Aligned to 17% ROE?

The guidance raise is modest, but it comes with a cleaner 2028 setup

HASI's guidance increase looks small at the margin, but the endpoint is more explicit: the company now targets 2028 adjusted EPS of $3.55 to $3.65, up from $3.50 to $3.60, while still aiming for adjusted ROE of at least 17.0% in 2028. That matters because it followed a quarter where adjusted EPS rose to $0.75 from $0.60 in Q2 2025, and managed assets of $17.6 billion grew 20% year over year.

The key question is no longer whether HASI has assets to deploy. It is whether earnings power is improving fast enough to support the higher target without leaning too heavily on equity dilution. If that balance holds, the guidance raise carries more weight than the narrow band suggests.

Stronger asset yields and tighter capital math make 17% ROE more tangible

Income growth is keeping pace with balance-sheet expansion

ROE does not come from simply adding assets. It comes from earning more on each dollar of capital. The last two quarters point in that direction.

In Q1, HASI delivered adjusted EPS of $0.77 and adjusted recurring net investment income of $101 million, up 29%. In Q2, adjusted recurring net investment income rose to $107 million, up 26%, while managed assets grew 20% year over year to $17.6 billion.

That combination matters. HASI reported new asset yields on portfolio investments above 10.5% in Q1 and above 11% in Q2. If those yields hold and funding costs stay controlled, management has a plausible mechanism for reaching its 2028 ROE target rather than relying on asset growth alone.

Funding discipline is improving the compounding case

This is where the setup looks more like a compounding story than a simple yield trade. HASI issued $1 billion in senior unsecured notes, redeemed its 8.00% senior unsecured notes due 2027, and after the quarter increased revolver capacity by $425 million to $2.25 billion. The company also said it had issued no new shares through its ATM year to date and expected minimal ATM issuances in 2026, even with a outlook for $2 billion to $3 billion in new balance sheet and CCH1 investments.

For bulls, that capital discipline matters. If HASI can keep deploying into higher-yielding assets while limiting dilution, the 17% ROE target becomes easier to defend.

The adjusted versus GAAP gap is still the main credibility test

The market is still weighing earnings quality

The biggest bear argument remains the same: the adjusted story is much stronger than the GAAP story. In Q1, HASI posted GAAP EPS of $(0.57) even while reporting Adjusted EPS of $0.77. In Q2, the contrast was still sharp, with GAAP-based net investment income of $9.9 million versus adjusted recurring net investment income of $107 million.

That does not automatically break the thesis, but it does mean investors are being asked to place more weight on adjusted metrics than they might prefer.

A strong quarter still did not unlock a major rerating

The market's hesitation showed up after Q1. HASI beat adjusted EPS expectations, posted a record adjusted ROE of 15.7%, and the stock still rose only 0.85% in aftermarket trading. That suggests investors are waiting for more proof that the adjusted compounding narrative can hold up across quarters.

What to watch in the next quarter

The thesis is still alive, but it now needs consistency. The most important signals are:

• whether asset yields and funding spreads stay supportive
• whether adjusted income keeps translating into cleaner earnings credibility
• whether capital remains disciplined enough to limit dilution
• whether insider and institutional ownership trends reinforce management's guidance

If those signals hold, the higher 2028 EPS range deserves more credit. If not, HASI may still look more like a yield story than a fully proven compounding story.